AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lym
Data from two Phase I/II trials presented at American Society of Hematology ...
2017-12-13
文传商讯
Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-
Phase I/II trial findings add to growing body of data on acalabrutinib clini...
2016-12-06
文传商讯
